Study at a glance
How was vitamin D studied in bone health and fractures?
This review compares mouse experiments on bone and mineral regulation with the VITAL human fracture trial. The experiments changed receptors, hormones or exposure to active vitamin D. VITAL tested additional daily vitamin D3 in 25,871 adults who were not selected for vitamin D deficiency, osteoporosis or low bone mass. These are different questions.
What happened to bone health in the mouse experiments?
Removing vitamin D receptors from the intestine reduced calcium absorption. Blood calcium remained normal under the main conditions, but the addition of minerals to bone worsened and fractures occurred in some mice. Other experiments showed that effects depended on the bone-cell type, developmental stage and mineral environment. A toxic dose of active vitamin D promoted bone breakdown through specific cell signals; this was not ordinary vitamin D3 supplementation.
Did vitamin D reduce fractures in the VITAL trial?
Over a median 5.3 years, added vitamin D3 did not clearly reduce total, outside-the-spine or hip fractures compared with placebo. First fractures occurred in 769 people assigned vitamin D and 782 assigned placebo. Some measurements of body chemicals changed without a demonstrated fracture benefit. Most participants did not have severe vitamin D deficiency, so the trial does not settle treatment of that condition.
What do these studies tell us about vitamin D and bone health?
Adding mineral to bone, breaking down and rebuilding bone tissue, and fractures are different outcomes. A normal blood calcium result does not guarantee normal bone stores, but the mouse findings are not a rule for diagnosing problems in people. The processes seen in experiments cannot override the human trial result, and that result does not erase what the experiments showed. These studies do not support a universal claim that vitamin D either builds or harms bone, or provide a personal treatment plan.
Read the full article below ↓Vitamin D’s relationship with bone depends on mineral supply, the cells receiving the signal and the outcome being measured. Mouse studies show how intestinal absorption, local receptor signalling and phosphate regulation influence skeletal mineralisation. A large human trial addresses a different question: whether adding daily vitamin D3 reduced fractures in adults not selected for deficiency or osteoporosis. The findings are complementary only when those distinctions remain visible. For the shorter account, see Vitamin D and Bone: Mineralisation, Cell Signalling and Fractures: Study Summary.
Bone mineralisation and fracture prevention are different questions
Vitamin D and Bone brings together mineral handling, bone-cell activity and structural integrity. Research can examine each at a different scale. Mineralisation concerns deposition of mineral in the bone matrix. Remodelling includes removal and replacement of bone tissue. Fracture is a clinical or structural event influenced by the resulting skeleton and the circumstances in which it is loaded.
A change in a resorption marker does not directly quantify fracture risk. More unmineralised osteoid is not interchangeable with a lower count of osteoblasts. Likewise, a molecular mechanism can be real without demonstrating that giving a supplement prevents fractures in an unselected population. The studies in this review help separate these questions rather than assuming that every favourable laboratory response predicts the same outcome.
The experimental exposures also differ. Removing VDR from a selected tissue, deleting a mineral-regulating hormone throughout an animal and administering a toxic dose of active calcitriol are not equivalents of routine oral vitamin D3. Vitamin D Activation provides the broader distinction between a precursor and its activated hormone; the identity and route of each intervention remain essential to interpreting the studies below.
This is an original VD3FL analysis of five primary publications. Material main articles and relevant supplements were examined during the evidence review. For the VITAL fracture report, the complete main text, tables and figure legends were available, but the figure graphics and supplementary files were not. The analysis is confined to the principal main-text estimates and does not claim verification of unavailable subgroup graphics or supplementary analyses.
Intestinal supply can determine how bone responds
Lieben and colleagues used mice with intestinal VDR deletion to reduce vitamin-D-dependent calcium absorption while retaining receptor signalling elsewhere. The model tests the consequences of impaired intestinal response, not the consequences of removing every VDR function in the animal. The wider experimental distinction is developed in Tissue-Specific VDR Physiology: Knockout and Rescue Evidence.
Serum calcium remained comparable with controls under the principal conditions, and serum phosphate was also maintained. PTH and active vitamin D increased, indicating a compensatory endocrine response. Yet bone mineral accumulation deteriorated. Trabecular bone volume and cortical thickness fell, cortical porosity increased and unmineralised matrix accumulated.
The researchers measured intestinal uptake using an oral calcium tracer, bone architecture by micro-CT, and matrix mineralisation by histological staining and sequential calcein labelling. These complementary assays separate impaired absorption, reduced bone volume and defective deposition. Skeletal growth was preserved despite the loss of mineralised bone, so normal growth was not evidence of normal bone quality.
The fracture observation makes the tissue consequence tangible: spontaneous fractures and healing calluses were seen in 10% of the examined intestinal-knockout mice and not in the controls. This does not establish an equivalent human fracture probability. It shows that the preserved serum concentration in this experiment did not imply preservation of the skeleton.
The distinction connects Vitamin D and Calcium with Vitamin D and Calcium Physiology. A blood concentration is a regulated measurement, whereas skeletal mineral content reflects accumulated tissue balance. The experiment cannot be reduced to the claim that normal serum calcium means adequate skeletal calcium stores, nor can it be used to diagnose concealed bone loss from a normal result alone.
The skeleton both released mineral and incorporated less
The intestinal-knockout phenotype included increased resorption-related measurements and reduced mineralisation. The investigators therefore considered two contributions to maintaining circulating calcium: release from existing bone and reduced incorporation into newly formed matrix. Both matter because bone balance is determined by more than one direction of mineral movement.
Serum CTX increased and cortical resorption cavities were prominent. However, not every osteoclast measurement moved in parallel; some supplementary measurements were unchanged or lower. CTX is a circulating marker, while cell counts and surfaces describe particular locations and stages. Their differences prevent a blanket statement that every measure of osteoclast formation or activity increased.
Bone formation markers also increased: serum osteocalcin, osteocalcin transcripts and the abundance of active-looking osteoblasts rose. In contrast, the early differentiation marker Runx2 and stromal-cell osteogenic differentiation in culture were not altered. This was increased turnover with inadequate mineral storage, not simply a failure to produce osteoblasts.
An intervention tested the proposed compensatory role of resorption. Zoledronic acid treatment from eight to fourteen weeks increased bone volume in intestinal-knockout mice but lowered their serum calcium; resorption was not completely normalised. The fall in circulating calcium when resorption was inhibited supports a contribution from skeletal release to maintaining that concentration. It does not establish a treatment strategy for humans.
The mineralisation experiments implicated extracellular pyrophosphate and related regulators, including ENPP3, ANK and osteopontin. Active-vitamin-D signalling in osteoblast-lineage cells was associated with increased inhibition of mineral incorporation under the studied conditions. These are more specific findings than a general assertion that vitamin D either builds or removes bone.
The pyrophosphate experiments went beyond an association. In differentiated osteoblast cultures, four days of 10 nM calcitriol increased extracellular pyrophosphate and reduced Alizarin-red-detected mineralisation. Adding tissue-nonspecific alkaline phosphatase, which degrades pyrophosphate, rescued mineralisation. VDR/RXR binding assays and reporter experiments also supported hormone-responsive regulatory regions near Enpp3 and Ank. These experiments link receptor-dependent transcription, a mineralisation inhibitor and a functional deposition endpoint, while leaving the full in-vivo contribution of each individual regulator unresolved.
Osteopontin expression increased and Phex expression decreased in the intestinal-knockout bones. PTH could contribute to the Phex decrease in culture, but it did not explain the osteopontin increase. Other tested mineralisation regulators were unchanged. The mechanism therefore involves selected pathways rather than uniform activation of every inhibitor.
A second mouse model removed VDR from mature osteoblasts and osteocytes using Dmp1-associated targeting. Baseline skeletal findings were largely normal, but loss of that signalling protected against the mineralisation impairment induced by intraperitoneal calcitriol at 0.5 micrograms/kg daily for one week. Osteoclast abundance increased in both genotypes; the rise in serum CTX was not statistically significant. No genotype difference was detected in these resorption measures, even though mineralisation was preserved in the knockout. The late-cell deletion therefore separated mineral incorporation from osteoclast output; it did not block every skeletal response to calcitriol. The contrast shows why the particular cell stage and experimental condition matter. It does not establish that bone-cell VDR is universally unnecessary or universally harmful.
The rescue diet contained 2% calcium, 1.25% phosphorus and 20% lactose and changed the phenotype by improving mineral availability under the experimental conditions. Because several dietary components changed, it is not a clean estimate of an isolated calcium-supplement effect in people. Severe low-calcium conditions in the same programme also produced marked illness and mortality; those extremes should not be presented as ordinary human dietary deficiency.
Osteoblast-lineage signalling can drive osteoclast output
Mori and colleagues investigated the proresorptive action of active calcitriol in mice. Their principal mechanistic regimen was 5 micrograms per kilogram daily for four days in eight-week-old animals. The authors explicitly studied a toxic active-hormone exposure, following pilot dose work in which still higher doses caused deaths. It would be misleading to translate this directly into a claim about ordinary cholecalciferol supplementation.
The study combined two ways of intervening in the proposed pathway. One used a neutralising antibody against RANKL, a signal involved in osteoclast formation. The other removed VDR from osteoblast-lineage cells using Osx-associated targeting. This allowed the investigators to distinguish the signalling cell population from the osteoclast output it influenced.
In controls, calcitriol increased osteoclast formation and serum CTX. Anti-RANKL pretreatment suppressed these responses. Osteoblast-lineage VDR deletion likewise prevented the main calcitriol-induced osteoclast and CTX changes. The result supports a mechanism in which receptor-dependent signalling in one cell lineage promotes a resorptive response in another.
TRAP-positive cell counts and serum CTX provided complementary measures of osteoclast abundance and resorption. Bone RANKL and cathepsin-K transcripts increased in controls, whereas OPG did not change. The RANKL and cathepsin-K responses were absent after osteoblast-lineage VDR deletion, while renal CYP24A1 induction persisted. That renal response is an important control: the receptor deletion did not abolish every tissue’s response to the administered hormone.
This is not evidence that the hormone acts only through osteoclasts. Anti-RANKL treatment only partly prevented the calcium and FGF23 effects, whereas the osteoblast-lineage receptor intervention affected a broader part of the response. Blocking a downstream resorptive route did not remove every systemic effect of the exposure.
Body-weight loss accompanied the toxic exposure and was attenuated by anti-RANKL treatment and absent in the receptor-deletion comparison. Weight change correlated with serum calcium across the pooled experiments, but that association alone cannot establish the entire toxicity pathway. The authors proposed FGF23-dependent renal calcium retention to explain residual hypercalcaemia after osteoclast blockade; this was a proposed explanation rather than a directly tested renal mechanism.
Small and uneven groups constrain precision, and one genetic comparison included both sexes. Animals that died at the higher exploratory doses were excluded from the displayed pilot dataset. The paper’s final schematic also incorporated earlier low-dose work from the same programme; those low-dose findings must not be presented as new experiments performed in this study.
The useful conclusion is therefore specific: under a toxic active-calcitriol regimen, osteoblast-lineage VDR and RANKL-dependent osteoclast formation contributed to the measured proresorptive response. The study does not provide a human fracture estimate or establish that nutritional vitamin D3 is generally harmful to bone. Vitamin D-Induced Hypercalcaemia: Mechanisms of Calcium Dysregulation: Full Study examines the wider calcium-dysregulation mechanisms relevant to interpreting excessive active-hormone exposure.
Cartilage contributes to developing bone and mineral signals
Masuyama and colleagues examined chondrocyte-specific VDR deletion in juvenile mice. The manipulated cells were in cartilage, rather than the mature osteoblast and osteocyte population targeted in Lieben’s second model. This difference in developmental compartment helps explain why the experiments address distinct functions.
The deletion was checked at DNA, RNA and functional-response levels, while VDR activity in osteoblasts, kidney and intestine was retained. CD31 staining assessed vascular invasion, TRAP staining identified osteoclasts, and histomorphometry measured bone structure. Trabecular bone volume was approximately 50% higher in neonatal and fifteen-day-old mutants, despite normal longitudinal growth and largely preserved growth-plate morphology. Osteoblast differentiation measures did not explain that increase.
Juvenile animals showed reduced vascular and osteoclast recruitment, with altered RANKL-associated responses. The study also found reduced osteoblast-associated FGF23 production and higher circulating phosphate and calcitriol. Calcium and PTH did not change in the same pattern. Local developmental signalling therefore had consequences extending to systemic mineral regulation.
In chondrocyte: splenocyte cocultures, calcitriol promoted osteoclast formation with control chondrocytes but not VDR-deficient chondrocytes. RANKL induction was lost while OPG expression remained unchanged; PGE2 still induced osteoclast formation in either genotype. This control makes the result specific to the vitamin-D-dependent route rather than a general inability of the mutant culture to support osteoclasts.
Coculture work supported communication between cartilage and bone-cell populations. However, the cartilage-derived factor responsible for the FGF23 effect remained unidentified. Preserved PGE2 responsiveness also limited the interpretation: the cells were not universally incapable of responding to every stimulus.
Several skeletal differences normalised by eight weeks. The findings should therefore remain attached to the juvenile stage and the particular targeting strategy. They do not demonstrate a persistent adult phenotype or fusion of adult mouse growth plates. Developmental recruitment, adult remodelling and long-term human fracture risk remain different questions.
Lieben and Masuyama belonged to the same Leuven research programme. Their models are complementary, but their publications should not be counted as independent laboratory replications of one result. The scientific value comes from the different tissue perturbations and the resulting distinctions in mineral handling.
FGF23 links phosphate handling with active vitamin D
Shimada’s whole-body Fgf23-knockout mice developed high phosphate and calcitriol, increased renal activating-enzyme expression and increased renal phosphate reabsorption. The kidney transporter NaPi-2a and measurements of phosphate handling supported that interpretation. Vitamin D and Phosphate Regulation provides the wider physiological setting for this feedback relationship.
Despite elevated circulating mineral-related signals, the animals had abnormal bone with reduced mineralised tissue and increased osteoid. Bone histomorphometry showed reduced mineralised bone volume even though total bone volume did not differ significantly. Both osteoblast and osteoclast surfaces were reduced. Tetracycline/calcein double labelling could not yield the usual mineralisation measures because labelled mineralising surfaces were absent. These findings identify low turnover and poor mineralisation rather than simply more resorption. Growth was impaired and survival was short. High concentrations of a circulating mineral or hormone therefore cannot be assumed to guarantee appropriate incorporation into skeletal tissue.
PTH fell later, while phosphate abnormalities were already evident earlier. A low-phosphate diet prolonged survival in some animals without correcting all abnormalities, including the elevated active-vitamin-D state. These observations limit any simple explanation that attributes the entire phenotype to one circulating measurement.
The global deletion and severe developmental illness are important boundaries. The study does not show that calcitriol alone caused every skeletal or systemic abnormality, and it is not a model of ordinary low vitamin D status. Its contribution is to demonstrate the importance of coordinated phosphate and active-vitamin-D regulation for the experimental animal’s skeletal and systemic state.
VITAL tested incident fractures in people
LeBoff and colleagues reported the fracture component of VITAL, a large randomised trial involving 25,871 US adults: men aged at least 50 and women aged at least 55. Participants received 2,000 IU vitamin D3 daily or placebo within a factorial trial that also randomised omega-3 supplementation. Median follow-up was 5.3 years.
Participants were not selected for vitamin D deficiency, osteoporosis or low bone mass. Mean baseline 25-hydroxyvitamin D among those measured was 30.7 ng/mL, and only 2.4% had values below 12 ng/mL. The population is therefore central to interpreting the result. This was not a trial designed specifically to treat severe deficiency or osteomalacia.
Outside vitamin D supplements up to 800 IU daily and calcium supplements up to 1,200 mg daily were permitted. Thus, the comparison was additional trial vitamin D against placebo under those background conditions, not necessarily vitamin D exposure against none. Treatment adherence was reported as 87.3% at two years and 85.4% at five years.
Vitamin D status was measured by liquid chromatography: tandem mass spectrometry calibrated to CDC standards. Randomisation followed a three-month placebo run-in that selected participants taking at least two-thirds of trial pills, which matters when generalising adherence to routine use.
Fractures were reported by participants and assessed through medical-record review and blinded central adjudication. The primary endpoints included fractures regardless of trauma level; they were not restricted to fragility fractures. The principal intention-to-treat analysis used Cox proportional-hazards models, preserving the randomised comparison while allowing different follow-up times. Not every reported event had records available: 87% of participants reporting fractures consented to review, and documentation was obtained for 91.3% of those. This qualification matters while still recognising the strength of a large randomised study with a clinical endpoint.
The principal fracture estimates were close to no difference
First incident total fractures occurred in 769 of 12,927 participants assigned vitamin D and 782 of 12,944 assigned placebo. The hazard ratio was 0.98, with a 95% confidence interval of 0.89 to 1.08 and p=.70. The estimate did not establish a reduction in total fractures.
The nonvertebral-fracture hazard ratio was 0.97, with a 95% confidence interval of 0.87 to 1.07. For hip fractures it was 1.01, with a wider interval of 0.70 to 1.47. The wider hip-fracture interval reflects greater uncertainty around that rarer outcome; it should not be treated as equally precise evidence about every fracture category.
The reported models accounted for age, sex, race or ethnic group and omega-3 assignment. These clinical comparisons are different from the cell and mouse perturbations described earlier. A null fracture result does not erase those mechanisms, while the existence of those mechanisms does not override the randomised fracture comparison.
Main-text sensitivity analyses did not change the conclusion when adherence or delayed effects were considered. Excluding toe, finger, skull, periprosthetic and pathological fractures also gave similar results: the total-fracture hazard ratio was 0.99 (95% CI 0.89 to 1.10). These additional analyses support the stability of the principal finding, although secondary and exploratory comparisons were not adjusted for multiple testing. The report found no substantial between-group difference in hypercalcaemia or kidney stones under this trial regimen.
In a measured subset, PTH decreased in the vitamin D group, while calcium did not change. This demonstrates a biochemical response alongside the absence of an established fracture benefit in the main comparison. It does not show that the PTH change mediated the fracture result or that a particular PTH target would improve outcomes.
The study cannot exclude benefit from treating severe deficiency, because that population was sparsely represented. It also does not answer every question about institutionalised adults, calcium co-treatment, other regimens or diagnosed skeletal disease. Those limits should accompany the result, without turning them into reasons to disregard the result for the population actually studied.
Integrating mechanisms and clinical outcomes
Bone Mineralisation, Turnover and Fractures Measure Different Outcomes explains why mineralisation, turnover and fractures need separate interpretation. The experimental studies identify how tissue-specific receptor signalling and mineral feedback can alter bone, while VITAL tests whether a particular additional supplement regimen changed a clinical outcome in a defined population.
Vitamin D and Endocrine Coordination: Compensation and Failure: Full Study develops the endocrine coordination question: a preserved circulating variable can coexist with tissue cost, and correcting one abnormality may leave others unresolved. That explanation helps connect intestinal supply and phosphate handling without repeating every bone-cell experiment.
Across the evidence, neither a universal bone-building claim nor a universal bone-harming claim is justified. Effects depend on the ligand, dose, tissue, developmental stage, mineral environment and measured endpoint. The contrast between toxic active calcitriol and daily nutritional vitamin D3 is especially important. They are different interventions, not contradictory descriptions of the same treatment.
Conclusion
Vitamin D-related signalling influences skeletal mineral supply, mineral deposition and cell-to-cell regulation in the selected experimental models. Those mechanisms depend on context and cannot be converted directly into a fracture-prevention claim. VITAL found no significant reduction in fractures with added daily vitamin D3 in adults not selected for deficiency or osteoporosis. The combined evidence supports a specific account of skeletal physiology while preserving the limits of clinical translation.
Primary source and publication details
LeBoff MS, Chou SH, Ratliff KA, Cook NR, Khurana B, Kim E, Cawthon PM, Bauer DC, Black D, Gallagher JC, Lee IM, Buring JE, Manson JE. Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. The New England journal of medicine. 2022;387(4):299-309. DOI 10.1056/nejmoa2202106. PMID 35939577.
Lieben L, Masuyama R, Torrekens S, Van Looveren R, Schrooten J, Baatsen P, Lafage-Proust MH, Dresselaers T, Feng JQ, Bonewald LF, Meyer MB, Pike JW, Bouillon R, Carmeliet G. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. The Journal of clinical investigation. 2012;122(5):1803-1815. DOI 10.1172/jci45890. PMID 22523068.
Masuyama R, Stockmans I, Torrekens S, Van Looveren R, Maes C, Carmeliet P, Bouillon R, Carmeliet G. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. The Journal of clinical investigation. 2006;116(12):3150-3159. DOI 10.1172/jci29463. PMID 17099775.
Mori T, Horibe K, Koide M, Uehara S, Yamamoto Y, Kato S, Yasuda H, Takahashi N, Udagawa N, Nakamichi Y. The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the Proresorptive Activity of 1α,25(OH)2D3 In Vivo. Endocrinology. 2020;161(11):bqaa178. DOI 10.1210/endocr/bqaa178. PMID 32987399.
Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. The Journal of clinical investigation. 2004;113(4):561-568. DOI 10.1172/jci19081. PMID 14966565.
Related reading
Ability of radiofrequency echographic multispectrometry to identify osteoporosis status in elderly women with type 2 diabetes
This study aimed to evaluate whether the use of the Radiofrequency Echographic multi spectrometry (REMS) technique may improve the identification of osteoporosis in T2DM patients.
Original paper ↗Read more →Caffeine is a risk factor for osteopenia of prematurity in preterm infants: a cohort study
Osteopenia of prematurity was evaluated using chest X-rays on a biweekly basis over 12 weeks of hospitalization.
Original paper ↗Read more →Effects of intermittent overload doses of oral vitamin D3 on serum 25(OH)D concentrations and the incidence rates of fractures, falls, and mortality in elderly individuals: A systematic review and meta-analysis
Therefore, the purpose of this study was to investigate the clinical effects and safety profile of vitamin D3 with a meta-analysis conducted under the specific conditions of loading dose and intermittent oral administration.
Original paper ↗Read more →Knowledge gap in a cross section of Irish general practitioners prescribing denosumab for osteoporosis
Denosumab is commonly used by general practitioners (GPs) in Ireland to treat osteoporosis though drug holidays are not recommended with rebound bone loss and risk of vertebral fractures if stopped.
Original paper ↗Read more →Lower preoperative vitamin D levels are associated with poor clinical outcomes in elderly patients with osteoporotic vertebral compression fractures after percutaneous vertebroplasty
This study evaluated the association between preoperative vitamin D status and postoperative pain and functional recovery following PVP.
Original paper ↗Read more →MTX Osteopathy Versus Osteoporosis Including Response to Treatment Data: A Retrospective Single Center Study Including 172 Patients
We compared patients suffering from MTX osteopathy to patients with osteoporosis (OPO).
Original paper ↗Read more →Pre-diagnostic vitamin D deficiency and subsequent thyroid cancer risk: a propensity-matched cohort study
This study aimed to examine the association between pre-diagnostic VDD and the risk of incident thyroid cancer over a 10-year follow-up period.
Original paper ↗Read more →Prediction of Osteoporotic Hip Fracture Outcome: Comparative Accuracy of 27 Immune-Inflammatory-Metabolic Markers and Related Conceptual Issues
In consecutive HF patient (n = 1273, mean age 82.9 ± 8.7 years, 73.5% females) demographics, medical history, laboratory parameters, and outcomes were recorded prospectively.
Original paper ↗Read more →Retinoids Promote Mouse Bone Marrow-Derived Macrophage Differentiation and Efferocytosis via Upregulating Bone Morphogenetic Protein-2 and Smad3
Thus, proper efferocytosis is a prerequisite for proper resolution of inflammation, and failure in efferocytosis is associated with the development of chronic inflammatory diseases.
Original paper ↗Read more →Risk Factors, Manifestation, and Awareness of Osteoporosis among Patients of Various Specialists in Switzerland: Results of a National Survey
Osteoporosis is the most common chronic metabolic bone disease, known to be underdiagnosed and undertreated in parts of the Swiss population.
Original paper ↗Read more →Secondary Hyperparathyroidism in Children with Mucolipidosis Type II (I-Cell Disease): Irish Experience
The aim of this study was to describe in detail the clinical cases of ML II presenting to a tertiary referral centre with biochemical and/or radiological features of hyperparathyroidism.
Original paper ↗Read more →Stability-Driven Osteoporosis Screening: Multi-View Consensus Feature Selection with External Validation and Sensitivity Analysis
Multiple predictor configurations, ranging from full-feature to minimal and near-minimal models, were evaluated using decision tree, support vector machine, k-nearest neighbor, naïve Bayes, and efficient linear classifiers.
Original paper ↗Read more →Stanniocalcin 1 and 1,25-dihydroxyvitamin D3 cooperatively regulate bone mineralization by osteoblasts
In this study, we investigated whether STC1 directly regulates osteoblast differentiation or reciprocally controls the effects of 1,25(OH)2D3 on osteoblasts to contribute to bone homeostasis.
Original paper ↗Read more →The Application of Machine Learning in Predicting Mortality Risk in Patients With Severe Femoral Neck Fractures: Prediction Model Development Study
Femoral neck fracture (FNF) accounts for approximately 3.58% of all fractures in the entire body, exhibiting an increasing trend each year.
Original paper ↗Read more →Vitamin D Alleviates Cadmium-Induced Inhibition of Chicken Bone Marrow Stromal Cells’ Osteogenic Differentiation In Vitro
In this study, the effect of Cd toxicity in vitro on osteogenic differentiation derived from BMSCs and the alleviating effect of lα, 25-(OH)2D3 were investigated.
Original paper ↗Read more →Vitamin D Enhanced the Osteogenic Differentiation of Cell Spheroids Composed of Bone Marrow Stem Cells
Background and Objectives: Vitamin D is a bone modulator widely used in regenerative medicine.
Original paper ↗Read more →Vitamin D receptor expression in human bone tissue and dose-dependent activation in resorbing osteoclasts
The effects of vitamin D on osteoblast mineralization are well documented.
Original paper ↗Read more →Vitamin D status and site-specific fracture pattern associations in older adults with fragility fractures: a cross-sectional analysis of 2543 patients
This study aimed to assess vitamin D status and investigate its variation across fracture sites in elderly patients with fragility fractures.
Original paper ↗Read more →The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the Proresorptive Activity of 1α,25(OH)2D3 In Vivo
Using osteoblast-lineage-specific VDR conditional knockout (Ob-VDR-cKO) mice, we examined whether proresorptive activity induced by the high-dose 1α,25(OH)2D3 was also mediated by VDR in osteoblast-lineage cells.
Original paper ↗Read more →Vitamin D and Bone: Mineralisation, Cell Signalling and Fractures: Study Summary
A short summary of vitamin D bone-cell and mineral-regulation studies alongside the VITAL fracture trial and its population limits.
Read more →Animal versus plant protein and adult bone health: A systematic review and meta-analysis from the National Osteoporosis Foundation
The aim was to conduct a systematic review and meta-analysis evaluating the effects of animal versus plant protein intake on bone mineral density (BMD), bone mineral content (BMC) and select bone biomarkers in healthy adults.
Original paper ↗Read more →Original sources
Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults
Published in The New England journal of medicine (2022).
Publication details
LeBoff MS, Chou SH, Ratliff KA, Cook NR, Khurana B, Kim E, Cawthon PM, Bauer DC, Black D, Gallagher JC, Lee IM, Buring JE, Manson JE. Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. The New England journal of medicine. 2022;387(4):299-309. DOI 10.1056/nejmoa2202106. PMID 35939577.
Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization
Published in The Journal of clinical investigation (2012).
Publication details
Lieben L, Masuyama R, Torrekens S, Van Looveren R, Schrooten J, Baatsen P, Lafage-Proust MH, Dresselaers T, Feng JQ, Bonewald LF, Meyer MB, Pike JW, Bouillon R, Carmeliet G. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. The Journal of clinical investigation. 2012;122(5):1803-1815. DOI 10.1172/jci45890. PMID 22523068.
Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts
Published in The Journal of clinical investigation (2006).
Publication details
Masuyama R, Stockmans I, Torrekens S, Van Looveren R, Maes C, Carmeliet P, Bouillon R, Carmeliet G. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. The Journal of clinical investigation. 2006;116(12):3150-3159. DOI 10.1172/jci29463. PMID 17099775.
The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the Proresorptive Activity of 1α,25(OH)2D3 In Vivo
Using osteoblast-lineage-specific VDR conditional knockout (Ob-VDR-cKO) mice, we examined whether proresorptive activity induced by the high-dose 1α,25(OH)2D3 was also mediated by VDR in osteoblast-lineage cells.
Publication details
Mori T, Horibe K, Koide M, Uehara S, Yamamoto Y, Kato S, Yasuda H, Takahashi N, Udagawa N, Nakamichi Y. The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the Proresorptive Activity of 1α,25(OH)2D3 In Vivo. Endocrinology. 2020;161(11):bqaa178. DOI 10.1210/endocr/bqaa178. PMID 32987399.
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism
Published in The Journal of clinical investigation (2004).
Publication details
Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. The Journal of clinical investigation. 2004;113(4):561-568. DOI 10.1172/jci19081. PMID 14966565.